RPRX · Royalty Pharma plc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (non-GAAP) non-GAAP | $736M | the second quarter of 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Portfolio Receipts $773M
-$37M Payments for operating and professional costs
= Adjusted EBITDA (non-GAAP) $736M
|
|||
| Capital Deployment | -$877M | six months ended June 30, 2026 | — |
|
|
|||
| Portfolio Cash Flow (non-GAAP) non-GAAP | $736M | the second quarter of 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Adjusted EBITDA (non-GAAP) $736M
+$0M Interest (paid)/received, net
= Portfolio Cash Flow (non-GAAP) $736M
|
|||
| Portfolio Receipts | $3.25B | FY 2025 | — |
| Royalty Receipts | $856M | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RPRX
this stock
Royalty Pharma plc
|
$35.54B | +59.9% | +5.1% | 33.1 | 2.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RPRX | +0.1% | +4.4% | +35.3% | +5.8% | +59.9% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +0.5% | -0.6% | +22.9% | +3.2% | +47.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.